Table 3 Multivariable analysis and propensity score matching based on HDMTX prophylaxis for time to isolated CNS relapse, systemic relapse, PFS, and OS.

From: High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma

  Multivariable analysis Propensity score matching
HR (85% CI) P HR (95% CI) P
Time to isolated CNS relapsea 0.16 (0.03–0.91) 0.039 0.06 (0.004–0.946) 0.046
Time to systemic relapseb 1.02 (0.50–2.06) 0.958 3.59 (0.69–18.74) 0.129
PFSc 0.60 (0.20–1.12) 0.106 1.12 (0.43–2.92) 0.818
OSd 0.61 (0.32–1.17) 0.135 0.63 (0.25–1.61) 0.332
  1. Multivariable model including all factors with P < 0.1 from the univariate analysis.
  2. aAdjusted for CNS-IPI score 4–6 vs 0–3, extranodal site involvement >1, high risk site involvement (bone marrow, breast, and testis).
  3. bAdjusted for IPI score 3–5 vs 0–2 and extranodal site involvement >1.
  4. cAdjusted for IPI score 3–5 vs 0–2, extranodal site involvement>1, high risk site involvement (bone marrow, breast, and testis).
  5. dAdjusted for IPI score 3–5.
  6. HR hazard ratio, CI confidence interval, PFS progression free survival, OS overall survival.